Army Contracts Meridian for Nerve Agent Antidote Shots

The deal is worth up to $75.2 million over the next year for the ATNAA auto-injector.

Updated on Nov. 17, 2026 in Military

Bold flat-color editorial illustration of a single olive-drab auto-injector standing centered against a deep slate field, evoking military preparedness against nerve agents.
The U.S. Army agreed to spend up to $75.2 million over the next year with St. Louis-based Meridian Medical Technologies, the sole maker of the ATNAA nerve agent antidote auto-injector for the military. AI Illustration. Upload story photo >

Live Poll

Should the U.S. government spend more on its military?

The U.S. military has agreed to spend up to $75.2 million with St. Louis-based Meridian Medical Technologies for nerve agent antidote injectors. Meridian is the only company that makes the ATNAA shot for the U.S. military.

Why it matters

Nerve agents can kill within minutes, so the speed of treatment is critical for troops. The contract reflects the military's reliance on a single supplier for a key battlefield medical device.

The ATNAA shot combines atropine and pralidoxime chloride in one needle, which a Saint Louis University study found cut the time needed to deliver the antidote in half. Meridian found in 2013 that seven of every 1,000 checked shots were not completely filled and rechecked 1.1 million shots afterward.

The players

Meridian Medical Technologies

A St. Louis-based maker of emergency medical devices, including the ATNAA nerve agent antidote auto-injector used by the U.S. military.

The details

The ATNAA shot resembles a thick marker pen; a soldier presses it hard against the thigh, and a spring drives the needle into the muscle to inject both drugs at once. The contract's maximum ceiling covers the new year, and the deal allows one additional year to be added after the second year.

Timeline

  1. December 2025: First year of the Meridian deal was signed, worth up to $72.9 million.

  2. October 2024: Britain punished Russian commanders over chemical attacks in Ukraine.

  3. 2013: Meridian found unfilled shots and rechecked 1.1 million shots.

  4. Nov. 15, 2027: Deadline for military orders under the contract.

Political Context

Britain's October 2024 punishment of Russian commanders over chemical attacks in Ukraine underscored the threat that prompted this procurement. The Army's continued reliance on a single supplier for the ATNAA shot raises questions about competition in the defense medical market.

The contract shapes which battlefield medical supplies service members can rely on, since the ATNAA shot is currently the only option the military buys. Taxpayers are funding the deal, which could total up to $226 million if all options are exercised.

The takeaway

Single-supplier contracts for critical medical devices concentrate both risk and cost, so readers should watch whether future orders broaden the supplier base. The speed-focused design of the ATNAA shot shows how small engineering changes can matter when minutes count.

Further reading

Explore more coverage in the Military section for context on defense procurement and battlefield medical readiness.

Source note: This article includes information reported by Defence Blog.

Live Poll

Should the U.S. government spend more on its military?